26 reports

Oral Contraceptive and Cancer Risks.

  • Chemotherapy
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

Use of oral contraceptive pills is a protective factor.

  • Chemotherapy
  • China
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd
  • Ltd Jiangsu Hengrui Medicine Co.

Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.

  • Cancer
  • Chemotherapy
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

Use of oral contraceptive pills Chapter IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND is a protective factor.

  • Chemotherapy
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

It takes medical research and development as core, makes self-made brands as main, and operates raw material medicines, western and Chinese medicines, health care products, medical equipments and contraceptives.

  • Chemotherapy
  • China
  • Supply
  • Tianjin Tianyao Pharmaceutical Co., Ltd
  • Zhejiang Expressway Co., Ltd.

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.

  • Chemotherapy
  • Amgen Inc.
  • Biocon Limited
  • Mylan Inc.
  • Roche Group

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.

  • Chemotherapy
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Disease overview

Roche is one of the major players in the market.

  • Cervical Cancer
  • Chemotherapy
  • World
  • Hoffmann-La Roche Inc.
  • Merck & Co., Inc.

The use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing the disease.

  • Chemotherapy
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.

Its highest selling products include Betaferon/ Betaseron (multiple sclerosis); YAZ/ Yasmin/ Yasminelle (hormonal contraceptive); Kogenate (hemophilia); Nexavar (cancer); Adalat (hypertension); and Mirena (hormonal contraceptive).

  • Chemotherapy
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sanofi S.A.

Following an initial one month lead-in period, eligible subjects were randomized ##:## to a single intratympanic injection of OTIVIDEX or placebo.

  • Chemotherapy
  • Therapy
  • United States
  • Product Initiative
  • Otonomy, Inc.

Use of birth control contraceptives and hormonal therapy after menopause increase the risk for developing breast cancer as they contain synthetic sex hormones.

  • Chemotherapy
  • United States
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

Mithra is optimistic that its contraceptive ring will be one of the first fully bioequivalent products for NuvaRing® in the key US market, which would lead to increased milestone payments and boost the revenues for the Myring® production at the Mithra CDMO.

  • Chemotherapy
  • Therapy
  • United States
  • Company
  • Novocure

The prominent features of this report are - ##.

  • Blood Disease
  • Chemotherapy
  • Clinical Trial
  • Leukemia
  • Novartis AG

Median follow-up was ## ## months (IQR ## ##-## ##).

  • Chemotherapy
  • Hepatitis
  • Therapy
  • United States
  • Company Operations

Higher estrogen levels can be associated with the use of hormone replacement therapy and oral contraceptives (Institute of Medicine Committee, 1991).

  • Breast Cancer
  • Cancer
  • Chemotherapy
  • Pathology
  • Therapy

GlaxoSmithKline registered a Phase I open-label, non-randomized, sequential, two-period, repeat-dose study to evaluate the pharmacokinetics and safety of trametinib on combined oral contraceptive (norethindrone plus ethinyl estradiol) in female subjects with solid tumors.

  • Chemotherapy
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative

Median follow-up was ## ## months (IQR ## ##-## ##).

  • Chemotherapy
  • Lung Cancer
  • United States
  • Company Operations
  • Product Initiative

ASTRAZENECA REGISTERED A PHASE I SINGLE-BLIND, PLACEBO-CONTROLLED, ##-PERIOD, FIXED SEQUENCE STUDY TO EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF COADMINISTRATION OF FOSTAMATINIB ## MG TWICE DAILY ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE IN HEALTHY FEMALE SUBJECTS.

  • Chemotherapy
  • Hospital
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

GlaxoSmithKline registered a Phase I open-label, non-randomized, sequential, two-period, repeatdose study to evaluate the pharmacokinetics and safety of trametinib on combined oral contraceptive (norethindrone plus ethinyl estradiol) in female subjects with solid tumors.

  • Chemotherapy
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative

ORAL CONTRACEPTIVE USE HAS BEEN LINKED WITH A REDUCED RISK OF DEVELOPING OC AS A RESULT OF ITS IMPACT ON SEX HORMONE PRODUCTION.

  • Chemotherapy
  • Clinical Trial
  • United States
  • Company
  • AstraZeneca PLC

The prominent features of this report are - ##.

  • Cancer
  • Chemotherapy
  • United States
  • World
  • Product Initiative

Group ## (G##) received ofatumumab on Day ## of Cycle ##, and Imbruvica on Day ## of Cycle ##.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative

In 2011, Arno reported that onapristone ER was originally being developed by Schering AG for potential use as a contraceptive and an anti-endocrine treatment of breast cancer.

  • Cancer
  • Chemotherapy
  • Hormone
  • United States
  • Novartis AG

In 2011, Arno reported that onapristone ER was originally being developed by Schering AG for potential use as a contraceptive and an anti-endocrine treatment of breast cancer.

  • Chemotherapy
  • Prostate Cancer
  • United States
  • Company
  • Company Operations

CYTRX CORPORATION DAIICHI SANKYO COMPANY, LIMITED ELEISON PHARMACEUTICALS LLC Preclinical Discovery Total Company Name ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Cancer
  • Chemotherapy
  • United States
  • Company
  • Product Initiative